Informationen:
Fehler:
ID
14171
Beschreibung
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02029417
Link
https://clinicaltrials.gov/show/NCT02029417
Stichworte
Versionen (1)
- 02.04.16 02.04.16 -
Hochgeladen am
2. April 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome NCT02029417
Eligibility Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome NCT02029417
Ähnliche Modelle
Eligibility Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome NCT02029417
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Induction Chemotherapy
Item
patients who are not eligible for standard induction chemotherapy (or any standard therapy known to be life prolonging) because of poor performance status, significant tissue comorbidities, or unfavorable risk of disease
boolean
C3179010 (UMLS CUI [1])
diagnosis of acute myeloid leukemia
Item
have an unequivocal histologic diagnosis of acute myeloid leukemia (aml) (including secondary aml)
boolean
C0023467 (UMLS CUI [1])
Therapy naive
Item
no prior therapy for aml except hydroxyurea to control counts
boolean
C0919936 (UMLS CUI [1])
Contraceptive methods
Item
must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
boolean
C0700589 (UMLS CUI [1])
informed consent
Item
subject or legal representative must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure
boolean
C0021430 (UMLS CUI [1])
Acute Promyelocytic Leukemia
Item
subjects with the diagnosis of acute promyelocytic leukemia (t[15;17])
boolean
C0023487 (UMLS CUI [1])
Protocol Compliance
Item
unwilling or unable to follow protocol requirements
boolean
C0525058 (UMLS CUI [1,1])
C0009488 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,2])
Non-Compliance With Study Drug
Item
any condition which in the investigator's opinion deems the subject an unsuitable candidate to receive study drug
boolean
C1709261 (UMLS CUI [1])
Sickle cell SC disease
Item
patients with sickle cell disease and sickle cell crisis
boolean
C0853729 (UMLS CUI [1])
Investigational New Drugs
Item
received an investigational agent for another disease within 30 days prior to enrollment
boolean
C0013230 (UMLS CUI [1])
Communicable Diseases
Item
the patient has an uncontrolled and active infection that would preclude study conduct and assessment
boolean
C0009450 (UMLS CUI [1])